MGRX vs TDOC

For growth investors, Teladoc Health, Inc.

(TDOC) is the stronger pick with -1. 5% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). Analysts rate Teladoc Health, Inc. (TDOC) a "Hold" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Teladoc Health, Inc.

(TDOC) delivered a total return of -95. 5%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: TDOC returned -37. 3% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mangoceuticals, Inc.

(MGRX) is the lower-risk stock at 0. 90β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 112% more volatile than MGRX relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Teladoc Health, Inc.

(TDOC) is pulling ahead at -1. 5% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to 48. 7% for Mangoceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teladoc Health, Inc.

(TDOC) is the more profitable company, earning -7. 9% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps -7. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TDOC leads at -10. 4% versus -1294. 4% for MGRX. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MGRX (100.

0% yield) pays a dividend. TDOC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mangoceuticals, Inc.

(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 4%, TDOC: -37. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MGRX is a small-cap income-oriented stock; TDOC is a small-cap quality compounder stock. MGRX pays a dividend while TDOC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.